Back to top
more

Amarin (AMRN)

(Delayed Data from NSDQ)

$0.87 USD

0.87
490,626

+0.01 (1.72%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $0.90 +0.03 (2.87%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AMRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Amarin Corporation PLC [AMRN]

Reports for Purchase

Showing records 181 - 200 ( 353 total )

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 181

09/06/2019

Company Report

Pages: 9

An Ounce of Preparation Is Worth a Pound of Cure

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 182

08/21/2019

Company Report

Pages: 8

Cardio Docs Jump on the Wagon Ahead of AdCom

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 183

08/21/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 184

08/15/2019

Industry Report

Pages: 4

Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 185

08/14/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 186

08/13/2019

Company Report

Pages: 10

Let''s Get to Know the AdCom Review Members

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 187

08/09/2019

Daily Note

Pages: 5

Makes Hay While the AdCom Sun Shines

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 188

08/09/2019

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 189

08/09/2019

Daily Note

Pages: 3

Management Doesn’t Skip a Beat, As Vascepa AdCom Is Announced; Reit Buy and $51 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 190

08/01/2019

Company Report

Pages: 6

Vascepa Launch in Infancy, Pivotal Events on Near- Term Horizon, in Our View; Reit Buy and $51 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 191

08/01/2019

Company Report

Pages: 9

2Q19 - Ten Reasons Why Vascepa Brings Home the Bacon

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 192

08/01/2019

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 193

07/26/2019

Company Report

Pages: 7

What Happens If AstraZeneca Launches Epanova? A Look at How Amarin’s IP May Give It the Upper Hand

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 194

07/03/2019

Company Report

Pages: 6

Updated Revenue Guidance Consistent With Proprietary OM-3 Survey; Reit Buy and $51 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 195

07/03/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 196

07/02/2019

Company Report

Pages: 7

Crosses Its T''s and Dots Its I''s

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 197

06/26/2019

Company Report

Pages: 22

Confidence in Vascepa Growth Reaffirmed by Proprietary 100-Physician Survey; Reit Buy and $51 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 75.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 198

06/17/2019

Company Report

Pages: 65

We initiate coverage with a Buy rating and $31/share price target

Provider: Roth Capital Partners, Inc.

Analyst: RAHIMI Y

Price: 150.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 199

05/02/2019

Company Report

Pages: 6

Positive Revenue and Expansion Opportunities Met With Conservative Guidance, in our View; Reit Buy and $51 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Amarin Corporation PLC

Industry: Medical - Biomedical and Genetics

Record: 200

04/01/2019

Daily Note

Pages: 3

Shifting Aspects of CV Risk Reduction Landscape, As Vascepa sNDA Submitted to FDA; Reit Buy and $51 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party